RT Journal Article
SR Electronic
T1 Pacritinib abrogates the lupus phenotype in ABIN1[D485N] mice
JF Lupus Science & Medicine
JO Lupus Sci Med
FD Lupus Foundation of America
SP e000822
DO 10.1136/lupus-2022-000822
VO 10
IS 1
A1 Tsvetana Petrova
A1 Clara Figueras-Vadillo
A1 Sambit K Nanda
A1 Cheryl Scudamore
A1 Philip Cohen
YR 2023
UL http://lupus.bmj.com/content/10/1/e000822.abstract
AB Objective The aim of the study was to investigate whether the IRAK1/JAK2/Flt3 inhibitor pacritinib prevents disease development in the lupus-prone ABIN1[D485N] knock-in mouse.Methods ABIN1[D485N] knock-in mice aged 8 weeks were fed for 10 weeks on a diet containing pacritinib. Body weight was monitored, and serum collected at the end to measure pacritinib, autoantibody and immunoglobulin levels. Splenic immune cell populations were analysed, and the kidney, liver and lungs examined for pathology.Results Pacritinib prevented multiple facets of the lupus phenotype in ABIN1[D485N] knock-in mice, including splenomegaly, expansion of splenic germinal centre B cells, follicular T helper cells, and neutrophils, elevated serum levels of double-stranded DNA antibodies and immunoglobulins, glomerular IgA and lung inflammation.Conclusions Pacritinib may be useful for the treatment of multiorgan inflammation in patients with lupus.